Abstract
Introduction: New data continue to emerge related to safety and efficacy of emerging SGLT1 and 2 inhibitors. We sought to assess the effect of online education designed to improve the knowledge and confidence of primary care physicians (PCPs), diabetologists and endocrinologists (D/Es), and nurses/nurse practitioners (NPs) in emerging therapies for diabetes management. Methods: The education consisted of a 30-minute continuing medical education (CME)-certified roundtable discussion among 3 expert faculty. A 3-question knowledge and 1-question confidence linked pre-/post-assessment study design with McNemar’s chi-squared test (5% significance level, P <.05) assessed educational effect. The activity launched September 26, 2018 and data collected through October 5, 2018. Results: Improvements were demonstrated by all specialties (PCP N=324, D/E N=104, nurse/NP N=1519): 24% more PCPs (P<.0001), 20% more D/Es (P=.0032), and 4% more nurses/NPs (P=.0251) correctly identified the mechanism of action of dual SGLT1/SGLT2 inhibitors. 38% of PCPs, 27% of D/Es, and 28% of NPs reported increased confidence in the treatment of type 1 diabetes with non-insulin therapies, specifically SGLT type 1 and SGLT type 2 inhibition. Continued knowledge gaps were identified for all specialties: 72% of PCPs, 65% of D/Es, and 66% of nurses/NPs failed to recognize safety and efficacy data for an emerging dual SGLT1/SGLT2 inhibitors. 40% of PCPs, 17% of D/Es, and 55% of nurses/NPs incorrectly identified a candidate for dual SGLT1/SGLT2 therapy 45% of PCPs, 32% of D/Es, and 69% of nurses/NPs failed to recognize the mechanism of action of dual SGLT1/SGLT2 inhibitors. Conclusion: This study demonstrates the success of an online CME-certified roundtable discussion on improving clinical knowledge and confidence of PCPs, D/Es, and nurses/NPs related to dual SGLT1/SGLT2 inhibitors when treating patients with T1D. Continued knowledge gaps were identified for future education. Disclosure A. Larkin: None. M. LaCouture: None. A. Le: None. Funding Sanofi U.S.; Lexicon Pharmaceuticals
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
